HFrEF

Effect of sodium-glucose cotransporter 2 inhibitors on left atrial remodeling and prognosis in patients with type 2 diabetes and heart failure with reduced ejection fraction.

I meccanismi fisiopatologici della riduzione del numero di ospedalizzazioni e della mortalità cardiovascolare documentata dagli inibitori del cotrasportatore 2 del sodio-glucosio (SGLT2i) restano sconosciuti. Lo scopo del presente studio retrospettivo (2019-2022) è stato quello di valutare se gli SGLT2i migliorino il rimodellamento dell’atrio sinistro nei pazienti con diabete di tipo 2 e insufficienza cardiaca con frazione di eiezione ridotta (HFrEF). L’endpoint primario dello studio era la mortalità per tutte le cause.

LEGGI TUTTO »

Quantified mitral regurgitation and left atrial function in heart failure with reduced ejection fraction: interplay and outcome implications

Aims: The clinical and prognostic importance of functional mitral regurgitation (FMR) in heart failure patients with reduced ejection fraction, (HFrEF) has been highly debated. This study aims to define FMR linkage to cardiovascular (CV) outcomes and the interplay with left atrial (LA) function in a prospective cohort of consecutive HFrEF outpatients.

Methods and results: Overall, 286 consecutive outpatients, with chronic HFrEF, were prospectively enrolled. FMR was quantified by effective regurgitant orifice area (EROA). Global peak atrial longitudinal strain (PALS) was measured by speckle tracking echocardiography. The primary endpoint was a composite of congestive heart failure hospitalization or CV death. During a mean follow-up of 4.1 ± 1.5 years, the primary endpoint occurred in 99 patients (35%). The spline modelling of the risk by FMR severity showed an excess event risk starting at about the EROA value of 0.1 cm2 . There was a remarkable graded association between the EROA strata, even if tested per 0.1 cm2 increase, and the risk of CV events (hazard ratio [HR] EROA per 0.10 cm2 increase: 1.42, 95% confidence interval [CI] 1.19-1.68; p<0.0001). E><0.0001). EROA ≥0.30 cm2 was associated with CV events regardless of LA function (HR 2.34, 95% CI 1.29-4.19; p=0.005). Less severe FMR (EROA ≥0.10 cm2 ) was associated with a dismal outcome only in patients with reduced LA function (PALS <14% (5-year CV event rate 51 ± 4%); conversely, the risk of events was relative reduced when preserved global PALS and FMR coexisted (5-year CV event rate 38 ± 6%). Conclusions: Our results refine the independent association between FMR and CV outcome among HFrEF outpatients. Within a moderate EROA range, LA function mitigates the clinical consequences of mitral regurgitation, providing measurable proof of the interplay between regurgitation and LA compliance.

LEGGI TUTTO »

Rivascolarizzazione con bypass e angioplastica nel paziente coronaropatico con scompenso cardiaco: una analisi del registro SCAAR.

Nei pazienti con cardiopatia ischemica e scompenso cardiaco la rivascolarizzazione con bypass aortocoronarico (CABG) migliora la prognosi rispetto alla terapia medica ottimale, come dimostrato dallo studio STICH ((Velazquez EJ, Lee KL, Jones RH, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med 2016;374:1511–1520. )). Non esiste, tuttavia, analoga documentazione per l’angioplastica coronarica (PCI) che è peraltro la modalità di rivascolarizzazione più ampiamente effettuata. Inoltre, non vi è alcuno studio di confronto tra CABG e PCI in questa popolazione ad alto rischio.

LEGGI TUTTO »
Cerca un articolo
Gli articoli più letti
Rubriche
Leggi i tuoi articoli salvati
La tua lista è vuota